Does Syndax Pharmaceuticals (SNDX) Pay a Dividend? (2026)
Last updated November 2026
Short answer
No. Syndax Pharmaceuticals (SNDX) pays no dividend, so the yield is 0% and the position generates no income while you hold it. Its earnings position, net loss of $49.4M, or $0.55 per share, in 3Q26, level with 2Q26; trailing twelve-month net loss of ~$209.5M, or ~$2.37 per share. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. There is no P/E, and there has never been an annual profit; consensus has the loss narrowing to ~$0.65 a share in 2027., is the reason that matters most: companies typically start paying only once earnings and free cash flow are durable enough to support a standing commitment. All of SNDX's return has to come from the share price. Verify the current policy on SNDX's investor relations page.
Does Syndax Pharmaceuticals (SNDX) pay a dividend?
No. There is no dividend on SNDX in our data and the yield is 0%. Roughly 2.8 times trailing sales is a low multiple for a biotech growing revenue at ~82%, and the reasons are visible in the structure and the pipeline more than the growth rate. Half the franchise arrives as a profit share, the Royalty Pharma instrument skims 13.8% of US Niktimvo sales before anything reaches Syndax, both drugs are approved only in later-line settings, the October 2026 IPF failure removed one route to a much larger market, and the frontline cGVHD readout has moved into 2027. At ~$806M, the market value is only about $255M above the ~$551M of cash and investments, while ~$589M of debt sits ahead of shareholders. Eleven covering analysts carry a mean target near $34, a frontline-expansion number and not a run-rate one.
Plainly: if you are holding SNDX for income, it does not provide any. The only way a position in it puts cash in your pocket is if you sell shares.
Why SNDX pays no dividend
Syndax Pharmaceuticals's earnings position (net loss of $49.4M, or $0.55 per share, in 3Q26, level with 2Q26; trailing twelve-month net loss of ~$209.5M, or ~$2.37 per share. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. There is no P/E, and there has never been an annual profit; consensus has the loss narrowing to ~$0.65 a share in 2027.) is the constraint. On cash flow: cash, cash equivalents and investments of about $551M at September 30, 2026, down from $575.1M at June 30 and up from $394.1M at December 31, 2025 after the $250M convertible issue. Trailing operating cash burn was ~$177M and free cash flow ~-$113M. Total debt of ~$589M, mainly the Royalty Pharma royalty financing liability and the 2.25% convertible notes due 2031; stockholders' equity was just $15.1M at June 30, 2026.. A dividend is a standing commitment that a board is very reluctant to cut once started, because a cut is read as a signal about the business. Companies therefore wait until profits and free cash flow are durable before starting one, and many never do, preferring buybacks, which can be paused without the same signalling cost.
Retaining cash is not a weakness in itself. A company that can reinvest a dollar at a high return creates more value by keeping it than by paying it out. The question is whether Syndax Pharmaceuticals is actually earning that return on what it reinvests, which is a business question, not a dividend question.
What would have to change for SNDX to start paying
Consistent profitability first, then free cash flow that comfortably exceeds what the business needs to keep growing, and then a management view that it has run out of better uses for the money. Those show up in the quarterly numbers well before any announcement, so the results are the place to watch. The press releases come later. We are not predicting whether or when that happens.
Where investors get income instead
The common approach is to hold SNDX for the growth exposure and get income from somewhere else in the portfolio, so each position does one job. The income side means dividend-paying stocks, dividend ETFs, or short-term bond and Treasury funds, sized so the income side covers what you need.
- Best dividend stocks for individual payers with long records.
- Best dividend ETFs to get a spread of payers in one holding.
- Best ETFs for monthly income if the timing of the cash matters to you.
Walnut is informational and is not an investment adviser. None of these are recommendations.
Tax: what a zero-dividend stock changes
With no dividend there is no income to report while you hold SNDX, so nothing is taxable until you sell. At sale you owe capital-gains tax on the gain, at long-term rates if you held for more than a year. Compared with a dividend payer in a taxable account, which generates a tax bill every year whether you spend the cash or reinvest it, that deferral is a small structural advantage. See how stocks are taxed. This is not tax advice.
The bottom line on the SNDX dividend
There is not one. Syndax Pharmaceuticals (SNDX) is a total-return holding: it either works through the share price or it does not work. If you own it, own it for that reason, and build the income part of your portfolio elsewhere. For the full picture see the SNDX guide. Walnut can show how SNDX fits your real portfolio. It is not an investment adviser.
Your questions about Syndax Pharmaceuticals
Ask Walnut's AI anything about SNDX and see how it fits what you own.
FAQ
Does Syndax Pharmaceuticals (SNDX) pay a dividend?
+
No. Syndax Pharmaceuticals has no dividend on record, so the yield is 0% and holding SNDX produces no income. Syndax Pharmaceuticals is not consistently profitable yet (net loss of $49.4M, or $0.55 per share, in 3Q26, level with 2Q26; trailing twelve-month net loss of ~$209.5M, or ~$2.37 per share. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. There is no P/E, and there has never been an annual profit; consensus has the loss narrowing to ~$0.65 a share in 2027.), and companies do not usually start returning cash before earnings are durable. Every dollar of return from SNDX has to come from the share price. Verify the current policy on SNDX's investor relations page, since a board can start a dividend at any time.
Why doesn't SNDX pay a dividend?
+
Syndax Pharmaceuticals is not consistently profitable yet (net loss of $49.4M, or $0.55 per share, in 3Q26, level with 2Q26; trailing twelve-month net loss of ~$209.5M, or ~$2.37 per share. Full-year 2025 net loss was $285.4M and 2024 was $318.8M. There is no P/E, and there has never been an annual profit; consensus has the loss narrowing to ~$0.65 a share in 2027.), and companies do not usually start returning cash before earnings are durable. Its free cash flow position (cash, cash equivalents and investments of about $551M at September 30, 2026, down from $575.1M at June 30 and up from $394.1M at December 31, 2025 after the $250M convertible issue. Trailing operating cash burn was ~$177M and free cash flow ~-$113M. Total debt of ~$589M, mainly the Royalty Pharma royalty financing liability and the 2.25% convertible notes due 2031; stockholders' equity was just $15.1M at June 30, 2026.) is the constraint that matters most here: a dividend is a standing commitment, and starting one before cash generation is reliable would mean funding it from the balance sheet. Paying nothing is a deliberate choice, not a failure. A growth company that can reinvest at high returns creates more value per dollar retained than it would by handing that dollar to shareholders.
Will SNDX ever pay a dividend?
+
Nobody can say, and we will not guess. What usually has to happen first is a stretch of durable profitability and positive free cash flow, with enough left over after reinvestment that the company runs out of better uses for the money. Those show up in the quarterly results well before any announcement. Companies also often start with buybacks before a dividend, because a buyback carries no ongoing commitment.
What is SNDX's dividend yield?
+
0%. There is no dividend, so there is no yield. This matters for planning: if you are building an income portfolio, SNDX contributes nothing to the income side and its entire contribution is price return. It also means the position generates no taxable income while you hold it.
How do I get income if I own SNDX?
+
The usual approach is to pair a non-payer like SNDX with holdings that do pay: dividend stocks, dividend ETFs, or bond funds, sized so the income side of the portfolio meets your needs while the growth side stays intact. Some investors sell covered calls on positions they hold, though that caps the upside that is the whole reason to own a growth name. See our guides to the best dividend stocks and best dividend ETFs. Walnut is not an investment adviser.
Do I owe tax on SNDX if it pays no dividend?
+
Not while you hold it. With no dividend there is no income to report, so nothing is taxable until you sell. At that point you owe capital-gains tax on the gain, at long-term rates if you held for more than a year and at ordinary-income rates if you did not. That deferral is a genuine, if minor, advantage of non-payers in a taxable account. This is not tax advice.
Is SNDX a bad stock for income investors?
+
It is the wrong tool for that job, which is not the same as a bad company. If you need cash from your portfolio, a stock paying nothing forces you to sell shares to generate it, which means selling into whatever price the market happens to offer. Investors who want SNDX's growth exposure and also want income typically hold both kinds of position and give each one job.
Does SNDX pay a dividend?
+
No. Syndax has never paid a dividend and does not currently generate net income, so there is no distributable profit. The company is spending roughly $400M a year on research and selling costs against ~$290M of trailing revenue and is funding the gap from a cash and investments balance of about $551M at September 30, 2026, built partly from a $350M royalty monetisation and $250M of convertible notes. Both of those instruments carry claims that rank ahead of shareholders: the notes pay 2.25% semi-annual cash interest, and Royalty Pharma takes 13.8% of US Niktimvo net sales up to an $822.5M cap. Companies at this stage of a launch generally reinvest any surplus into trials rather than returning it, and Syndax's stated priority is reaching profitability rather than distributions.
Walnut is informational, not investment advice. Dividend figures on this page come from a November 2026 data pull and are approximate; verify the current yield, amount, schedule, and policy with SNDX's investor relations page or your broker before acting on them.